Steinberg Global Asset Management Raised Its Merck & Co (MRK) Position; Last Week Celyad SA (CYAD) Analysts

May 22, 2018 - By Pete Kolinski

Merck & Co., Inc. (NYSE:MRK) Logo

Among 2 analysts covering Celyad SA (NASDAQ:CYAD), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Celyad SA had 3 analyst reports since August 27, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray on Thursday, August 31 with “Buy”. The firm earned “Buy” rating on Friday, April 27 by Piper Jaffray. See Celyad SA (NASDAQ:CYAD) latest ratings:

27/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $74.0000 Maintain

Steinberg Global Asset Management increased Merck & Co Inc (MRK) stake by 24.88% reported in 2017Q4 SEC filing. Steinberg Global Asset Management acquired 30,012 shares as Merck & Co Inc (MRK)’s stock declined 4.63%. The Steinberg Global Asset Management holds 150,623 shares with $8.48M value, up from 120,611 last quarter. Merck & Co Inc now has $158.35 billion valuation. The stock increased 0.50% or $0.29 during the last trading session, reaching $58.86. About 2.20M shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since May 22, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Celyad SA, a biopharmaceutical company, focuses on engineered cell therapy treatments. The company has market cap of $345.76 million. It operates in two divisions, Cardiology and Immuno-oncology. It currently has negative earnings. The companyÂ’s lead product candidate in cardiovascular disease is C-Cure, an autologous cell therapy for the treatment of patients with ischemic heart failure.

The stock increased 2.12% or $0.6 during the last trading session, reaching $28.85. About 21,701 shares traded or 148.27% up from the average. Celyad SA (NASDAQ:CYAD) has 0.00% since May 22, 2017 and is . It has underperformed by 11.55% the S&P500.

More notable recent Celyad SA (NASDAQ:CYAD) news were published by: Seekingalpha.com which released: “Celyad -3.3% after announcing 1.8M-unit offering” on May 15, 2018, also Globenewswire.com with their article: “Celyad announces pricing of $47.3 million global offering” published on May 17, 2018, Nasdaq.com published: “Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials” on May 03, 2018. More interesting news about Celyad SA (NASDAQ:CYAD) were released by: Nasdaq.com and their article: “Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed …” published on April 27, 2018 as well as Benzinga.com‘s news article titled: “23 Stocks Moving In Monday’s Pre-Market Session” with publication date: May 21, 2018.

Investors sentiment decreased to 0.94 in Q4 2017. Its down 0.12, from 1.06 in 2017Q3. It fall, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. New England Private Wealth Lc accumulated 9,148 shares. Guinness Asset Limited has 183,190 shares for 2.17% of their portfolio. Nomura Asset invested in 0.79% or 1.22M shares. Eos Management LP owns 0.13% invested in Merck & Co., Inc. (NYSE:MRK) for 6,979 shares. Smith Asset Mngmt Group Incorporated LP holds 355,520 shares. Ascend Cap Limited Liability Com holds 0.78% or 369,628 shares. Cadence Comml Bank Na stated it has 1.62% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Stillwater Cap Advisors Ltd holds 236,803 shares or 3.13% of its portfolio. Timber Creek Cap Limited Liability Corporation accumulated 0.16% or 4,572 shares. Daiwa Sb Invs reported 145,960 shares stake. Payden And Rygel holds 1.72% or 351,700 shares. Jupiter Asset Ltd, a United Kingdom-based fund reported 141,455 shares. Johnson Inv Counsel reported 0.12% stake. Chicago Equity Partners Limited Liability Com accumulated 0.59% or 342,600 shares. Outfitter Advsrs Ltd holds 55,108 shares.

Steinberg Global Asset Management decreased Occidental Pete Corp Del (NYSE:OXY) stake by 4,372 shares to 102,659 valued at $7.56M in 2017Q4. It also reduced Proshares Tr stake by 592,029 shares and now owns 44,935 shares. Vanguard Scottsdale Fds (VCSH) was reduced too.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Livetradingnews.com which released: “Merck & Co., Inc. (NYSE:MRK) Trending Upwards” on May 18, 2018, also Seekingalpha.com with their article: “New Ebola outbreak hits Congo” published on May 13, 2018, 247Wallst.com published: “What to Look For in the Merck and Pfizer Reports Tuesday Morning” on April 30, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Seekingalpha.com and their article: “Congo’s Ebola outbreak in ‘new phase'” published on May 17, 2018 as well as Investorplace.com‘s news article titled: “7 ‘Blue-Chip Stocks’ That Aren’t Blue Chips at All” with publication date: May 21, 2018.

Among 24 analysts covering Merck & Co. Inc. (NYSE:MRK), 21 have Buy rating, 0 Sell and 3 Hold. Therefore 88% are positive. Merck & Co. Inc. had 90 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Monday, October 23 by Leerink Swann. The firm earned “Equal-Weight” rating on Wednesday, February 7 by Morgan Stanley. The firm has “Hold” rating given on Tuesday, June 14 by Jefferies. Barclays Capital maintained Merck & Co., Inc. (NYSE:MRK) on Friday, September 9 with “Overweight” rating. The rating was maintained by Piper Jaffray with “Buy” on Thursday, October 26. As per Thursday, April 5, the company rating was upgraded by Barclays Capital. The firm has “Overweight” rating given on Thursday, January 12 by Morgan Stanley. On Monday, July 17 the stock rating was maintained by Deutsche Bank with “Hold”. On Monday, February 26 the stock rating was maintained by Jefferies with “Hold”. BMO Capital Markets maintained Merck & Co., Inc. (NYSE:MRK) on Friday, July 28 with “Buy” rating.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>